Amsel Medical plans to leverage its patented technology in three distinct verticals including: 1.) sales of venous product (2023), 2.) sales to the military; leveraging DoD supported non-dilutive funds and Amsel’s sole source designation 3.) licensing technology to strategic partners or build out deep product portfolio. This strategy allows us to focus on the venous market for which the management team has intimate knowledge as well as partnership opportunities for risk diversification with strategics and the military.
The Amsel Medical SCureClamp, which has 15 issued and allowed patents, is a mechanical solution that can be delivered percutaneously making it a simpler, faster and less invasive procedure. It is the only treatment procedure for varicose veins that does not destroy or remove the vein. The SCureClamp mechanical action extends the forces in the tissue without crushing or destroying it, thus preserving the targeted vessel while eliminating the risk associated with surgery. Amsel provides an opportunity for a minimally invasive rapid and locally deployed clamping device that mechanically closes the vessel and enables the patient to walk out minutes after treatment without dependence on an inflammatory reaction in the vessel lumen for permanent clamping.
Success will be achieved by offering an innovative approach to current thermal, gluing, or surgical stripping methods overcoming key inherent limitations. All other procedures either remove or destroy the vein. The SCureClamp interdigitation mechanical tissue clamping attaches tissue in a minimally invasive atraumatic manner and is delivered through an 18G needle (≈1mm).
Direct sales of our clamp for treating chronic venous disease (CVD) will be made to 5,000+ vein centers. These are free standing centers that are already called on by independent distributors and allows Amsel to break into the market without the need for a dedicated sales team. These vein centers are predominantly run by Vascular and General Surgeons that are also usually on staff at the local hospitals. We invasion the office-based physician introducing the Amsel product to the local hospital which would eliminate the need for the reps to cold call on the hospital. The Amsel management team developed the market leading endovenous laser system at AngioDynamics and has strong relationships with Key Opinion Leaders (LOL’s). We have selected KOLs in 12 sites globally as early adopters. They will drive clinical use experience, present at scientific symposia and publish to build awareness and customer acquisition. Our first full year goal is to establish our 1st - 50 centers averaging just 2 procedures per week for $4m in reorders. U.S. sales will achieve a gross margin exceeding 85%.
Amsel is also engaged with the U.S. DoD through a non-dilutive grant to develop a new version of its technology to be a temporary occluder, SCureTO while achieving a sole source supplier designation. Deaths associated with junctional and non-compressible hemorrhage in the battlefield prior to surgical intervention are extremely high, with a greater than 60% mortality amongst US combatants. Junctional and non-compressible hemorrhage due to trauma is also a major cause of morbidity and mortality for civilian victims, so the ability to rapidly reduce blood loss and improve survival, while reducing metabolic impacts from ischemia has broad significance. Amsel, supported by non-dilutive DoD funding is leveraging the atraumatic clamping aspect of its device in an adjustable embodiment that is deployable upstream of the injury site like a “vessel specific torniquet” and limits downstream blood flow while enabling some periodic profusion, to reduce limb loss and other metabolic complications.
Amsel’s technology also addresses a deep pipeline of applications such as in laparoscopic and robotic surgery. The company believes these applications can be monetized via strategic partnerships including licensing, distribution, or investment opportunities.